CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Seeking Alpha Healthcare
Original article

Teva, Polpharma ink licensing pact for biosimilar targeting Roche’s Ocrevus

PartnershipOcrevusPositive
AI Analysis

Summary

Teva Pharmaceutical and Polpharma have entered into a licensing agreement for a biosimilar targeting Roche's Ocrevus. The deal represents a partnership between the two companies in the biosimilar space.

Importance:6/10
Sentiment:
0.50
biosimilarlicensingpartnershipOcrevus
Related Companies

Read the original article

Published by Seeking Alpha Healthcare on July 9, 2026 1:25 PM

Read Original